Secukinumab for rheumatology: development and its potential place in therapy

References

• ScottDLWolfeFHuizingaTWRheumatoid arthritisLancet201037697461094110820870100
   PubMed Web of Science ®Google Scholar
• McInnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med2011365232205221922150039
   PubMed Web of Science ®Google Scholar
• KlareskogLAmaraKMalmströmVAdaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritisCurr Opin Rheumatol2014261727924257366
   PubMed Web of Science ®Google Scholar
• EderLChandranVPelletFHuman leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasisAnn Rheum Dis2012711505521900282
   PubMed Web of Science ®Google Scholar
• BrownMAKennaTWordsworthBPGenetics of ankylosing spondylitis–insights into pathogenesisNat Rev Rheumatol2016122819126439405
   PubMed Web of Science ®Google Scholar
• KaneDStaffordLBresnihanBFitzGeraldOA prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experienceRheumatology (Oxford)200342121460146814523223
   PubMed Web of Science ®Google Scholar
• van der HeijdeDBellamyNCalinADougadosMKhanMAvan der LindenSPreliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working GroupJ Rheumatol19972411222522299375888
   PubMed Web of Science ®Google Scholar
• ColebatchANMarksJLEdwardsCJSafety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)Cochrane Database Syst Rev201111CD00887222071858
   PubMed Web of Science ®Google Scholar
• van der HeijdeDBrebanMHalterDMaintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabRheumatology (Oxford)20155471210121925541333
   PubMed Web of Science ®Google Scholar
• ScirèCACaporaliRSarzi-PuttiniPMonitornet projectDrug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet databaseClin Exp Rheumatol201331685786323981363
   PubMed Web of Science ®Google Scholar
• O’DellJRMikulsTRTaylorTHCSP 551 RACAT InvestigatorsTherapies for active rheumatoid arthritis after methotrexate failureN Engl J Med2013369430731823755969
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• NamJLRamiroSGaujoux-VialaCEfficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis201473351652824399231
   PubMed Web of Science ®Google Scholar
• KoendersMIvan den BergWBNovel therapeutic targets in rheumatoid arthritisTrends Pharmacol Sci201536418919525732812
   PubMed Web of Science ®Google Scholar
• SieperJPorter-BrownBThompsonLHarariODougadosMAssessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trialsAnn Rheum Dis20147319510023765873
   PubMed Web of Science ®Google Scholar
• SongIHHeldmannFRudwaleitMTreatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot studyAnn Rheum Dis20117061108111021415053
   PubMed Web of Science ®Google Scholar
• SongIHHeldmannFRudwaleitMOne-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flareAnn Rheum Dis201372230530622887847
   PubMed Web of Science ®Google Scholar
• Jimenez-BojEStammTASadlonovaMRituximab in psoriatic arthritis: an exploratory evaluationAnn Rheum Dis201271111868187122833373
   PubMed Web of Science ®Google Scholar
• MeasePGenoveseMCGladsteinGAbatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialArthritis Rheum201163493994821128258
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABPSUMMIT 1 Study GroupEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet2013382989478078923769296
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232
   PubMed Web of Science ®Google Scholar
• Celgene CorporationStudy of Apremilast to Treat Subjects With Active Ankylosing Spondylitis (POSTURE) Available from: https://clinicaltrials.gov/ct2/show/NCT01583374
   Google Scholar
• U.S. Food and Drug AdministrationFDA approves new psoriasis drug Cosentyx Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm
   Google Scholar
• NovartisNovartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US Available from: https://www.novartis.com/news/media-releases/novartis-receives-two-new-fda-approvals-cosentyx-treat-patients-ankylosing
   Google Scholar
• AggarwalSGurneyALIL-17: prototype member of an emerging cytokine familyJ Leukoc Biol20027111811781375
   PubMed Web of Science ®Google Scholar
• RouvierELucianiMFMattéiMGDenizotFGolsteinPCTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri geneJ Immunol199315012544554568390535
   PubMed Web of Science ®Google Scholar
• HarringtonLEHattonRDManganPRInterleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNat Immunol20056111123113216200070
   PubMed Web of Science ®Google Scholar
• ParkHLiZYangXOA distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17Nat Immunol20056111133114116200068
   PubMed Web of Science ®Google Scholar
• GladiatorAWanglerNTrautwein-WeidnerKLeibundGut-LandmannSCutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infectionJ Immunol2013190252152523255360
   PubMed Web of Science ®Google Scholar
• FerrettiSBonneauODuboisGRJonesCETrifilieffAIL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible triggerJ Immunol200317042106211212574382
   PubMed Web of Science ®Google Scholar
• BucklandJNew role for mast cells as IL-17-expressing effector cells in established RANat Rev Rheumatol20106524320440895
   PubMedGoogle Scholar
• SchwandnerRYamaguchiKCaoZRequirement of tumor necrosis factor receptor-associated factor (TRAF) 6 in interleukin 17 signal transductionJ Exp Med200019171233124010748240
   PubMed Web of Science ®Google Scholar
• GaffenSLStructure and signalling in the IL-17 receptor familyNat Rev Immunol20099855656719575028
   PubMed Web of Science ®Google Scholar
• MurphyCALangrishCLChenYDivergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammationJ Exp Med2003198121951195714662908
   PubMed Web of Science ®Google Scholar
• CuaDJSherlockJChenYInterleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature2003421692474474812610626
   PubMed Web of Science ®Google Scholar
• IvanovIIMcKenzieBSZhouLThe orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cellsCell200612661121113316990136
   PubMed Web of Science ®Google Scholar
• ManelNUnutmazDLittmanDRThe differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammatNat Immunol20089664164918454151
   PubMed Web of Science ®Google Scholar
• YePRodriguezFHKanalySRequirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defenseJ Exp Med2001194451952711514607
   PubMed Web of Science ®Google Scholar
• HuangWNaLFidelPLSchwarzenbergerPRequirement of interleukin-17A for systemic anti-Candida albicans host defense in miceJ Infect Dis2004190362463115243941
   PubMed Web of Science ®Google Scholar
• OuyangWKollsJKZhengYThe biological functions of T helper 17 cell effector cytokines in inflammationImmunity200828445446718400188
   PubMed Web of Science ®Google Scholar
• MilnerJDBrenchleyJMLaurenceAImpaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndromeNature2008452718877377618337720
   PubMed Web of Science ®Google Scholar
• MaCSChewGYSimpsonNDeficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3J Exp Med200820571551155718591410
   PubMed Web of Science ®Google Scholar
• BurkettPRMeyer zu HorsteGKuchrooVKPouring fuel on the fire: Th17 cells, the environment, and autoimmunityJ Clin Invest201512562211221925961452
   PubMed Web of Science ®Google Scholar
• WuHJIvanovIIDarceJGut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cellsImmunity201032681582720620945
   PubMed Web of Science ®Google Scholar
• KirkhamBWKavanaughAReichKInterleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritisImmunology2014141213314223819583
   PubMed Web of Science ®Google Scholar
• FossiezFDjossouOChomaratPT cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokinesJ Exp Med19961836259326038676080
   PubMed Web of Science ®Google Scholar
• KotakeSUdagawaNTakahashiNIL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJ Clin Invest199910391345135210225978
   PubMed Web of Science ®Google Scholar
• ChabaudMMiossecPThe combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo modelArthritis Rheum20014461293130311407688
   PubMed Web of Science ®Google Scholar
• LeGrandAFermorBFinkCInterleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisciArthritis Rheum20014492078208311592370
   PubMed Web of Science ®Google Scholar
• KoshyPJHendersonNLoganCLifePFCawstonTERowanADInterleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokinesAnn Rheum Dis200261870471312117676
   PubMed Web of Science ®Google Scholar
• Van BezooijenRLVan Der Wee-PalsLPapapoulosSELöwikCWInterleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitroAnn Rheum Dis2002611087087612228154
   PubMed Web of Science ®Google Scholar
• ChabaudMDurandJMBuchsNHuman interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synoviumArthritis Rheum199942596397010323452
   PubMed Web of Science ®Google Scholar
• ZiolkowskaMKocALuszczykiewiczGHigh levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanismJ Immunol200016452832283810679127
   PubMed Web of Science ®Google Scholar
• GullickNJAbozaidHSJayarajDMEnhanced and persistent levels of interleukin (IL)-17+ CD4+ T cells and serum IL-17 in patients with early inflammatory arthritisClin Exp Immunol2013174229230123815507
   PubMed Web of Science ®Google Scholar
• ShenHXiaLLuJXiaoWInfliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritisJ Investig Med2010587905908
   PubMed Web of Science ®Google Scholar
• ChenDYChenYMChenHHHsiehCWLinCCLanJLIncreasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapyArthritis Res Ther2011134R12621801431
   PubMed Web of Science ®Google Scholar
• AlzabinSAbrahamSMTaherTEIncomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathwayAnn Rheum Dis201271101741174822550316
   PubMed Web of Science ®Google Scholar
• HullDNWilliamsROPathanEAlzabinSAbrahamSTaylorPCAnti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritisClin Exp Immunol2015181340140625766640
   PubMed Web of Science ®Google Scholar
• MenonBGullickNJWalterGJInterleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progressionArthritis Rheumatol20146651272128124470327
   PubMed Web of Science ®Google Scholar
• Van BaarsenLGMLebreMCvan der CoelenDSnoekBCGerlagDMTakPPIL-17 levels in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: target validation in various forms of arthritisAnn Rheum Dis201170A79
   Web of Science ®Google Scholar
• HüffmeierUUebeSEkiciABCommon variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasisNat Genet2010421199699920953186
   PubMed Web of Science ®Google Scholar
• RuedaBOrozcoGRayaEThe IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitisAnn Rheum Dis200867101451145418199597
   PubMed Web of Science ®Google Scholar
• NakaeSNambuASudoKIwakuraYSuppression of immune induction of collagen-induced arthritis in IL-17-deficient miceJ Immunol2003171116173617714634133
   PubMed Web of Science ®Google Scholar
• NakaeSSaijoSHoraiRSudoKMoriSIwakuraYIL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonistProc Natl Acad Sci U S A2003100105986599012721360
   PubMed Web of Science ®Google Scholar
• KoendersMIKollsJKOppers-WalgreenBInterleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritisArthritis Rheum200552103239324716200598
   PubMed Web of Science ®Google Scholar
• LubbertsEKoendersMIOppers-WalgreenBTreatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosionArthritis Rheum200450265065914872510
   PubMed Web of Science ®Google Scholar
• KoendersMIDevesaIMarijnissenRJInterleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient miceArthritis Rheum200858113461347018975337
   PubMed Web of Science ®Google Scholar
• KoendersMILubbertsEOppers-WalgreenBBlocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1Am J Pathol2005167114114915972960
   PubMed Web of Science ®Google Scholar
• KoendersMIMarijnissenRJDevesaITumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritisArthritis Rheum20116382329233921520013
   PubMed Web of Science ®Google Scholar
• Plater-ZyberkCJoostenLAHelsenMMKoendersMIBaeuerlePAvan den BergWBCombined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse modelAnn Rheum Dis200968572172818495731
   PubMed Web of Science ®Google Scholar
• van NieuwenhuijzeAEvan de LooFAWalgreenBComplementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritisArthritis Res Ther20151716326081345
   PubMed Web of Science ®Google Scholar
• RuutuMThomasGSteckRβ-glucan triggers spondyloarthritis and Crohn’s disease-like ileitis in SKG miceArthritis Rheum20126472211222222328069
   PubMed Web of Science ®Google Scholar
• BenhamHRehaumeLMHasnainSZInterleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG miceArthritis Rheumatol20146671755176724664521
   PubMed Web of Science ®Google Scholar
• LangleyRGElewskiBELebwohlMERASURE Study GroupFIXTURE Study GroupSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar
• GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnn Rheum Dis201372686386922730366
   PubMed Web of Science ®Google Scholar
• MeasePJMcInnesIBKirkhamBFUTURE 1 Study GroupSecukinumab inhibition of interleukin-17A in patients with psoriatic arthritisN Engl J Med2015373141329133926422723
   PubMed Web of Science ®Google Scholar
• McInnesIBMeasePJKirkhamBFUTURE 2 Study GroupSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538699991137114626135703
   PubMed Web of Science ®Google Scholar
• BaetenDLBraunJBaraliakosXSecukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosingArthritis Rheumatol201466S10S360
   Google Scholar
• BraunJDeodharAASieperJSecukinumab significantly improves signs and symptoms of active ankylosing spondylitis: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous loading and maintenance dosing [abstract]Arthritis Rheumatol201567suppl 10
   Google Scholar
• BurmesterGRDurezPShestakovaGAssociation of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritisRheumatology (Oxford)2016551495526268815
   PubMed Web of Science ®Google Scholar
• LebwohlMStroberBMenterAPhase 3 studies comparing brodalumab with ustekinumab in psoriasisN Engl J Med2015373141318132826422722
   PubMed Web of Science ®Google Scholar
• AmgenAmgen to Terminate Participation in Co-development and Commercialization of Brodalumab [press release]Thousand Oaks, CAPRNewswire2015522 Available from: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2052862
   Google Scholar
• DaneshMJKimballABBrodalumab and suicidal ideation in the context of a recent economic crisis in the United StatesJ Am Acad Dermatol201674119019226702804
   PubMed Web of Science ®Google Scholar
• HueberWPatelDDDryjaTEffects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitisSci Transl Med201025252ra72
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGSigurgeirssonBEfficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyBr J Dermatol2013168241242123106107
   PubMed Web of Science ®Google Scholar
• BlauveltAPrinzJCGottliebABFEATURE Study GroupSecukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)Br J Dermatol2015172248449325132411
   PubMed Web of Science ®Google Scholar
• GenoveseMCDurezPRichardsHBOne-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled studyJ Rheumatol201441341442124429175
   PubMed Web of Science ®Google Scholar
• KoendersMIMarijnissenRJJoostenLAT cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralizationArthritis Rheum20126461762177022213107
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsEfficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents (REASSURE) Available from: https://clinicaltrials.gov/ct2/show/NCT01377012
   Google Scholar
• Novartis PharmaceuticalsSafety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA. (REASSURE-E) Available from: https://clinicaltrials.gov/ct2/show/NCT01901900
   Google Scholar
• McInnesIBSieperJBraunJEfficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialAnn Rheum Dis201473234935623361084
   PubMed Web of Science ®Google Scholar
• NovartisNovartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis Available from: https://www.novartis.com/news/media-releases/novartis-receives-two-landmark-european-approvals-cosentyx-treat-patients
   Google Scholar
• BaetenDBaraliakosXBraunJAnti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialLancet201338299061705171324035250
   PubMed Web of Science ®Google Scholar
• BaraliakosXBorahBBraunJLong-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational studyAnn Rheum Dis201675240841226248638
   PubMed Web of Science ®Google Scholar
• BaraliakosXDeodharAABraunJEffect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab [abstract]Arthritis Rheumatol201567suppl 10
   Google Scholar
• BaetenDSieperJBraunJMEASURE 1 Study GroupMEASURE 2 Study GroupSecukinumab, an interleukin-17A Inhibitor, in ankylosing spondylitisN Engl J Med2015373262534254826699169
   PubMed Web of Science ®Google Scholar
• HueberWSandsBELewitzkySSecukinumab in Crohn’s Disease Study GroupSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trialGut201261121693170022595313
   PubMed Web of Science ®Google Scholar
• TarganSRFeaganBGVermeireSA randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s diseaseGastroenterology2012143E26
   PubMed Web of Science ®Google Scholar
• O’ConnorWJrZenewiczLAFlavellRAThe dual nature of T(H)17 cells: shifting the focus to functionNat Immunol201011647147620485275
   PubMed Web of Science ®Google Scholar
• DinarelloCASimonAvan der MeerJWTreating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNat Rev Drug Discov201211863365222850787
   PubMed Web of Science ®Google Scholar
• BraunJvan den BergRBaraliakosX2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnn Rheum Dis201170689690421540199
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• SmolenJSBraunJDougadosMTreating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task forceAnn Rheum Dis201473161623749611
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232
   PubMed Web of Science ®Google Scholar